John S. Lazo

Q: What Schools Are Affiliated With John S. Lazo

John S. Lazo is affiliated with the following schools: Yale University, California Institute of Technology, University of Michigan, Misr International University, Stanford University, University of Virginia, Johns Hopkins University, University of Pittsburgh

John S. Lazo's AcademicInfluence.com Rankings

John S. Lazo

Chemistry

#2986

World Rank

#3964

Historical Rank

chemistry Degrees

John S. Lazo

Biology

#8500

World Rank

#11591

Historical Rank

Molecular Biology

#1106

World Rank

#1131

Historical Rank

Biochemistry

#1257

World Rank

#1376

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

John S. Lazo's Degrees

Masters Chemistry Stanford University

Why Is John S. Lazo Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John Stephen Lazo is an American pharmacologist noted for his work discovering the fundamental mechanisms of action of small molecule therapeutics and the factors that confer drug resistance. He is a professor emeritus of pharmacology at University of Virginia.

(See a Problem?)

John S. Lazo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Overexpression of metallothionein confers resistance to anticancer drugs. (1988) (617)
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. (1981) (607)
Chemical genetics of Plasmodium falciparum (2010) (528)
Low molecular weight inhibitors of Myc–Max interaction and function (2003) (393)
Enhanced Sensitivity to Oxidative Stress in Cultured Embryonic Cells from Transgenic Mice Deficient in Metallothionein I and II Genes (*) (1995) (315)
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. (2009) (311)
Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. (1995) (255)
22R-Hydroxycholesterol and 9-cis-Retinoic Acid Induce ATP-binding Cassette Transporter A1 Expression and Cholesterol Efflux in Brain Cells and Decrease Amyloid β Secretion* (2003) (241)
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages (2009) (229)
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease* (2004) (223)
Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. (1988) (203)
Diallyl trisulfide-induced G2–M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc25C (2005) (186)
Enhanced apoptosis in metallothionein null cells. (1997) (186)
Automated High-Content Live Animal Drug Screening Using C. elegans Expressing the Aggregation Prone Serpin α1-antitrypsin Z (2010) (184)
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. (2001) (183)
Molecular Actions and Targets for Cancer Chemotherapeutic Agents (1981) (180)
The Benzo[c]phenanthridine Alkaloid, Sanguinarine, Is a Selective, Cell-active Inhibitor of Mitogen-activated Protein Kinase Phosphatase-1* (2005) (177)
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. (2002) (176)
Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tert-butyl hydroperoxide toxicity. (1994) (173)
Improved low molecular weight Myc-Max inhibitors (2007) (158)
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. (2005) (152)
Drugging Undruggable Molecular Cancer Targets. (2016) (147)
Role of metallothionein in carcinogenesis. (1994) (142)
High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. (1987) (141)
Metallothioneins and cell death by anticancer drugs. (1995) (140)
Dual-specificity phosphatases as targets for antineoplastic agents (2002) (134)
Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. (2001) (131)
Automated image‐based phenotypic analysis in zebrafish embryos (2009) (130)
Potent and Selective Disruption of Protein Kinase D Functionality by a Benzoxoloazepinolone* (2008) (126)
Calmodulin: a potential target for cancer chemotherapeutic agents. (1986) (125)
Metallothionein null cells have increased sensitivity to anticancer drugs. (1995) (125)
Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. (1983) (122)
The Substrate Recognition Domains of the N-end Rule Pathway* (2009) (117)
Cationic Liposomes for Direct Gene Transfer in Therapy of Cancer and Other Diseases a (1994) (116)
The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. (1998) (114)
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice (2009) (105)
Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. (2008) (102)
Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. (2000) (101)
Protein kinase D as a potential new target for cancer therapy. (2010) (100)
The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. (1999) (98)
Bcl-2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat-induced apoptosis. (1997) (96)
Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease (1998) (95)
Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. (2005) (94)
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. (2007) (92)
The heat-shock response attenuates lipopolysaccharide-mediated apoptosis in cultured sheep pulmonary artery endothelial cells. (1996) (92)
Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family. (1989) (91)
In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization (2010) (91)
Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. (2010) (90)
Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility (2010) (90)
Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). (1990) (88)
Overexpression of metallothionein decreases sensitivity of pulmonary endothelial cells to oxidant injury. (1997) (87)
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. (2007) (85)
Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. (1990) (84)
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. (1996) (84)
Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. (2009) (83)
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. (1991) (82)
Redox Regulation of Cdc25B by Cell-Active Quinolinediones (2005) (79)
Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione* (2002) (79)
A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. (1990) (79)
Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. (1992) (77)
A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. (1997) (76)
Endothelial injury caused by antineoplastic agents. (1986) (75)
Random versus selective membrane phospholipid oxidation in apoptosis: role of phosphatidylserine. (1998) (73)
Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase (2004) (70)
Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. (2005) (70)
Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. (1995) (67)
Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening (2009) (66)
Development and optimization of high-throughput in vitro protein phosphatase screening assays (2007) (66)
Evidence of differential cisplatin‐DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines (1993) (66)
Increased expression of tissue inhibitor of metalloproteinases (TIMP-I) and metallothionein in murine lungs after hyperoxic exposure. (1994) (66)
Collagen is a survival factor against LPS-induced apoptosis in cultured sheep pulmonary artery endothelial cells. (1995) (64)
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. (2009) (63)
Acute pulmonary toxicity of bleomycin: DNA scission and matrix protein mRNA levels in bleomycin-sensitive and -resistant strains of mice. (1989) (62)
Identifying Actives from HTS Data Sets (2011) (61)
Targeted Deletion of the Metastasis-Associated Phosphatase Ptp4a3 (PRL-3) Suppresses Murine Colon Cancer (2013) (60)
Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen (2009) (60)
Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. (1996) (59)
Translocation of protein kinase C is associated with inhibition of 5-HT uptake by cultured endothelial cells. (1989) (59)
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells (2008) (57)
Integrins inhibit LPS-induced DNA strand breakage in cultured lung endothelial cells. (1996) (57)
Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. (1991) (56)
Redox regulation of copper-metallothionein. (1999) (56)
Building a Pharmacological Lexicon: Small Molecule Discovery in Academia (2007) (55)
Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. (1991) (55)
Analysis of the Role of Bleomycin Hydrolase in Antigen Presentation and the Generation of CD8 T Cell Responses1 (2007) (54)
Cell-active dual specificity phosphatase inhibitors identified by high-content screening. (2003) (53)
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. (1994) (53)
Protein phosphorylation in cultured endothelial cells (1986) (52)
General discussion 4 (1994) (52)
Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists. (1985) (52)
Synthesis and biological studies of simplified analogues of lyngbyatoxin A: Use of an isoxazoline-based indole synthesis. Quest for protein kinase C modulators (1989) (50)
MKP-8, a novel MAPK phosphatase that inhibits p38 kinase. (2005) (49)
Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. (1983) (48)
The SARS-CoV-2 spike protein subunit S1 induces COVID-19-like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells (2021) (48)
Book Review: Goodman and Gilman's The Pharmacological Basis of Therapeutics: Digital Edition, 11th Edition (2006) (48)
Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. (1988) (48)
A Target-Based High Throughput Screen Yields Trypanosoma brucei Hexokinase Small Molecule Inhibitors with Antiparasitic Activity (2010) (48)
Design, Synthesis, and Biological Evaluation of PKD Inhibitors (2011) (48)
Small molecule inhibitors of dual specificity protein phosphatases (2000) (48)
Identification of Epidermal Growth Factor Receptor as a Target of Cdc25A Protein Phosphatase* (2002) (48)
Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. (2003) (47)
Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. (2006) (47)
Spatial Analysis of Key Signaling Proteins by High-content Solid-phase Cytometry in Hep3B Cells Treated with an Inhibitor of Cdc25 Dual-specificity Phosphatases* (2001) (46)
Nucleocytoplasmic functionality of metallothionein. (1997) (46)
Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. (2014) (46)
Systems cell biology knowledge created from high content screening. (2005) (45)
Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity. (2013) (45)
Nucleophilic distribution of metallothionein in human tumor cells. (1996) (45)
Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase. (1987) (44)
Independent Mechanistic Inhibition of Cdc25 Phosphatases by a Natural Product Caulibugulone (2007) (44)
Bleomycin hydrolase activity in pulmonary cells. (1984) (43)
New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. (2001) (43)
Nitric oxide dissociates lipid oxidation from apoptosis and phosphatidylserine externalization during oxidative stress. (2000) (43)
Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. (2007) (42)
Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells. (1994) (42)
Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. (1989) (42)
Human bleomycin hydrolase regulates the secretion of amyloid precursor protein (2000) (42)
Protein-tyrosine Phosphatase 4A3 (PTP4A3) Promotes Vascular Endothelial Growth Factor Signaling and Enables Endothelial Cell Motility* (2014) (41)
Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. (1984) (41)
Bleomycin hydrolase activity and cytotoxicity in human tumors. (1982) (41)
Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion (2011) (40)
Increased lethality of calmodulin antagonists and bleomycin to human bone marrow and bleomycin-resistant malignant cells. (1986) (40)
Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. (1996) (40)
Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis. (1988) (40)
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids (2015) (40)
Simian virus 40-transformed metallothionein null cells showed increased sensitivity to cadmium but not to zinc, copper, mercury or nickel. (1999) (39)
Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors. (1997) (39)
Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogues of the protein kinase C activator lyngbyatoxin A. (1991) (38)
Pulmonary fate of [3H]bleomycin A2 in mice. (1984) (38)
Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B. (2008) (38)
Airing out an antioxidant role for the tumor suppressor p53. (2006) (37)
Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53 and hDM2 and Characterization of the Confirmed Hits (2010) (37)
Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor. (2016) (37)
Activation of the Raf‐1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells (2004) (37)
Combinatorial chemistry and contemporary pharmacology. (2000) (36)
Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin. (1994) (36)
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. (2007) (36)
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells. (1996) (36)
Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel (1997) (36)
NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors (2004) (36)
Reconstitution of apo-superoxide dismutase by nitric oxide-induced copper transfer from metallothioneins. (2000) (36)
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. (2009) (35)
Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength (2010) (35)
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs. (2001) (35)
Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D. (2011) (34)
Bifunctional anti/prooxidant potential of metallothionenin: redox signaling of copper binding and release. (1999) (34)
Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome (2012) (33)
Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis (2017) (33)
Synthesis and biological evaluation of caulibugulones A-E. (2004) (33)
Essential binding and functional domains of human bleomycin hydrolase. (1998) (33)
Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries (2008) (33)
Phosphatase of Regenerating Liver-1 Promotes Cell Migration and Invasion and Regulates Filamentous Actin Dynamics (2010) (32)
Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. (2015) (32)
Synthesis and biological evaluation of deoxypreussomerin A and palmarumycin CP1 and related naphthoquinone spiroketals (2001) (32)
Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. (1989) (31)
Organ Directed Toxicities of Anticancer Drugs (1988) (31)
Toward a Molecular Understanding of the Interaction of Dual Specificity Phosphatases with Substrates: Insights from Structure-Based Modeling and High Throughput Screening (2008) (30)
Small molecule targeting of PTPs in cancer. (2017) (30)
Synthesis of structural analogues of lyngbyatoxin A and their evaluation as activators of protein kinase C. (1991) (30)
Reduction in rabbit serum and pulmonary angiotensin converting enzyme activity after subacute bleomycin treatment. (1981) (30)
Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin. (1992) (29)
Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array. (2000) (29)
Drug discovery algorithm for cutaneous leishmaniasis. (2013) (29)
Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. (2011) (29)
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. (2010) (29)
Microtubule Binding and Disruption and Induction of Premature Senescence by Disorazole C1 (2009) (29)
An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9. (1998) (29)
Is Cdc25 a druggable target? (2008) (28)
Synthesis, molecular modeling, 2-D NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C (1993) (27)
Biochemical markers of bleomycin toxicity: clearance of [14C]-5-hydroxytryptamine and [3H]norepinephrine by rabbit lung in vivo. (1981) (27)
Selective oxidation and externalization of membrane phosphatidylserine: Bcl-2-induced potentiation of the final common pathway for apoptosis (1999) (27)
HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines. (2015) (27)
Multimodal control of Cdc25A by nitrosative stress. (2008) (27)
Integrin activation protects pulmonary endothelial cells from the genotoxic effects of bleomycin. (1997) (26)
Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells. (1985) (26)
Subcellular localization of metallothionein IIA in human bladder tumor cells using a novel epitope-specific antiserum. (1994) (26)
Antimitotic actions of a novel analog of the fungal metabolite palmarumycin CP1. (2001) (26)
Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1. (2000) (26)
Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor (2017) (26)
Murine strain differences in pulmonary bleomycin metabolism. (1991) (26)
Regulation of Cdc25A Half-life in Interphase by Cyclin-dependent Kinase 2 Activity* (2003) (26)
Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity. (1996) (25)
Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells. (2016) (25)
Energy‐dependent nuclear binding dictates metallothionein localization (2000) (25)
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. (2009) (24)
Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. (2016) (24)
A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. (2004) (24)
Angiotensin converting enzyme activity in mice after subacute bleomycin administration. (1981) (24)
Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione. (2002) (24)
Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases. (2001) (24)
Chemical modulation of bleomycin induced toxicity. (1986) (24)
Antitumor and toxic effects of combination chemotherapy with bleomycin and a phenothiazine anticalmodulin agent. (1988) (23)
Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine (2004) (23)
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase β (2004) (23)
Strategies for Discovery of Small Molecule Radiation Protectors and Radiation Mitigators (2011) (22)
In vivo circumvention of human colon carcinoma resistance to bleomycin. (1992) (22)
Phosphatases as targets for cancer treatment. (2009) (22)
A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos (2011) (22)
Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases. (1987) (22)
Metallothionein modulates the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine in mice. (1999) (22)
Four diterpenoid inhibitors of Cdc25B phosphatase from a marine anemone. (2005) (22)
Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus. (2012) (22)
Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype (2012) (22)
Structurally Unique Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1 Identified in a Pyrrole Carboxamide Library (2007) (22)
Discovery of Diverse Small Molecule Chemotypes with Cell-Based PKD1 Inhibitory Activity (2011) (21)
Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos. (1991) (21)
Dual G1 and G2/M phase inhibition by SC-ααδ9, a combinatorially derived Cdc25 phosphatase inhibitor (1999) (21)
Cell cycle dependent subcellular distribution of Cdc25B subtypes (1999) (21)
High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. (2014) (20)
Identification of Chemosensitivity Nodes for Vinblastine through Small Interfering RNA High-Throughput Screens (2011) (20)
Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors. (2006) (20)
Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets (2010) (20)
Cellular Analysis of Disorazole C1 and Structure–Activity Relationship of Analogs of the Natural Product (2006) (19)
Human bleomycin hydrolase binds ribosomal proteins. (1999) (19)
Separation of Cdc25 dual specificity phosphatase inhibition and DNA cleaving activities in a focused library of analogs of the antitumor antibiotic Dnacin (2002) (19)
Metabolic inactivation of bleomycin analogs by bleomycin hydrolase. (1988) (19)
Pharmacological modulators of DNA-interactive antitumor drugs. (1989) (19)
Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C. (1992) (19)
Protein Kinase C Inhibition by UCN-01 Induces Apoptosis in Human Glioma Cells in a Time-dependent Fashion (2004) (19)
Sesterterpenoids and an alkaloid from a Thorectandra sp. as inhibitors of the phosphatase Cdc25B. (2005) (18)
Astrogliosis and behavioral changes in mice lacking the neutral cysteine protease bleomycin hydrolase (2007) (18)
Cysteine 73 in bleomycin hydrolase is critical for amyloid precursor protein processing. (2001) (18)
The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells. (2003) (18)
Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase. (1997) (18)
Roadmap or roadkill: a pharmacologist's analysis of the NIH Molecular Libraries Initiative. (2006) (18)
New Approaches to Difficult Drug Targets: The Phosphatase Story (2017) (18)
Deletion of Ptp4a3 reduces clonogenicity and tumor-initiation ability of colitis-associated cancer cells in mice. (2014) (17)
Gene therapy for neoplastic diseases (1994) (17)
Acute pneumocyte injury, poly(ADP-ribose) polymerase activity, and pyridine nucleotide levels after in vitro exposure of murine lung slices to cyclophosphamide. (1994) (17)
The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents. (1990) (17)
Paraquat-induced phosphatidylserine oxidation and apoptosis are independent of activation of PLA2. (1998) (17)
Synthesis and phosphorylation of chromatin-associated proteins in cAMP-induced "differentiated" neuroblastoma cells in culture. (1976) (17)
General Discussion 3 (1994) (17)
Aromatase activity in human ovarian cancer (1987) (16)
Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1 (2010) (16)
Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284). (2007) (16)
Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents (2014) (16)
New glycolipid inhibitors of Myt1 kinase (2005) (16)
Solubilization of pulmonary angiotensin-converting enzyme with 1-O-n-octyl-beta-D-glucopyranoside. (1980) (16)
A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis. (2016) (16)
Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs, and cultured pulmonary artery endothelial cells. (2015) (16)
Metabolism of bleomycin and bleomycin like compounds (1987) (15)
Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimer's Disease and Brain Insulin Resistance, and Its Relation to Cancer. (2019) (15)
A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo. (2003) (15)
Neurite extension and malignancy of neuroblastoma cells after treatment with prostaglandin E1 and papaverine. (1977) (15)
Reduction in cell surface concanavalin A binding and mannose incorporation into glycoproteins of sarcoma 180 by 6-thioguanine. (1979) (14)
Inhibition of L-fucose incorporation into glycoprotein of Sarcoma 180 ascites cells by 6-thioguanine. (1977) (14)
Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets. (2005) (14)
Identification of Druggable Targets for Radiation Mitigation Using a Small Interfering RNA Screening Assay (2012) (14)
Disruption of Insulin-Like Growth Factor-1 Signaling and Down-Regulation of Cdc2 by SC-ααδ9, a Novel Small Molecule Antisignaling Agent Identified in a Targeted Array Library (1998) (14)
Synthetic Protection Short Interfering RNA Screen Reveals Glyburide as a Novel Radioprotector (2009) (14)
Interleukin-1 beta-mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum. (1994) (14)
2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. (2014) (14)
Pharmacologic Profiling of Phosphoinositide 3-Kinase Inhibitors as Mitigators of Ionizing Radiation–Induced Cell Death (2013) (14)
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis. (2007) (13)
Enhancement of experimental lung metastases by cultured B16 melanoma cells treated with (+/-)-1,2-bis(3,5-dioxopiperazin-1-y)propane (ICRF-159). (1978) (13)
The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity. (2002) (13)
Prolonged reduction in serum angiotensin converting enzyme activity after treatment of rabbits with bleomycin. (1983) (13)
NAD depletion after in vitro exposure of murine lung slices to bleomycin. (1993) (13)
Small molecule regulation of phosphatase-dependent cell signaling pathways. (2003) (13)
Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. (2010) (13)
Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease. (2010) (13)
Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. (1991) (13)
Neutralization of bleomycin hydrolase by an epitope-specific antibody. (1992) (13)
The role of metallothioneins in anticancer drug resistance. (1991) (13)
Phenotypic Screening Reveals Topoisomerase I as a Breast Cancer Stem Cell Therapeutic Target (2012) (13)
Initial single-strand DNA damage and cellular pharmacokinetics of bleomycin A2. (1989) (12)
Identification of Inhibitors of Trypanosoma brucei Hexokinases (2011) (12)
Synergy between microtubule destabilizing agents and neurokinin 1 receptor antagonists identified by an siRNA synthetic lethal screen (2009) (12)
The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. (1998) (12)
A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion (2018) (12)
Compound acquisition and prioritization algorithm for constructing structurally diverse compound libraries. (2011) (12)
Synthesis and Biological Activity of a Focused Library of Mitogen‐activated Protein Kinase Phosphatase Inhibitors (2007) (11)
Cell-active dual specificity phosphatase inhibitors identified by high-content screening. (2005) (11)
Substrate specificity of bleomycin hydrolase. (1989) (11)
Paraquat-induced phosphatidylserine oxidation and apoptosis are independent of activation of PLA2. (1998) (11)
Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1. (2007) (11)
Expression of Pulmonary Metallothionein Genes in Late Gestational Lambs (1992) (11)
Differential transactivation of human metallothionein-IIa in cisplatin-resistant and -sensitive cells. (1998) (10)
Evaluation of potential ionizing irradiation protectors and mitigators using clonogenic survival of human umbilical cord blood hematopoietic progenitor cells. (2013) (10)
Bleomycin and cyclophosphamide increase pulmonary type IV procollagen mRNA in mice. (1990) (9)
Nuclear localization of bacterial Streptoalloteichus hindustanus bleomycin resistance protein in mammalian cells. (1993) (9)
Gene Therapy and Endothelial Cell Targeting for Cancer (1994) (9)
A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD). (2009) (9)
Marine sesquiterpenoids that inhibit the lyase activity of DNA polymerase beta. (2004) (9)
Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors. (2019) (9)
In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors. (2019) (9)
Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase (2019) (9)
Discovery of protein kinase phosphatase inhibitors. (2007) (8)
Synthesis and Biological Evaluation of Deoxypreussomerin A and Palmarumycin CP1 and Related Naphthoquinone Spiroketals. (2001) (8)
Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. (1991) (8)
Generation and Characterization of PRL‐3 Knockout Mice (2010) (8)
Review: Drug Discovery Algorithm for Cutaneous Leishmaniasis (2013) (8)
Involvement of the cellular vacuolar system with the cytotoxicity of bleomycin-like agents. (1990) (8)
Solubilization of murine melanoma xylosyltransferase and galactosyltransferase activities and their inactivation by dialdehyde nucleosides. (1982) (7)
Involvement of Cdc 25 A Phosphatase in Hep 3 B Hepatoma Cell Growth Inhibition Induced by Novel K Vitamin Analogs 1 (2001) (7)
Identifying a Resistance Determinant for the Antimitotic Natural Products Disorazole C1 and A1 (2010) (7)
Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha. (2004) (7)
New Inhibitors of the Thioredoxin—Thioredoxin Reductase System Based on a Naphthoquinone Spiroketal Natural Product Lead. (2010) (7)
A three-dimensional dementia model reveals spontaneous cell cycle re-entry and a senescence-associated secretory phenotype (2020) (6)
Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases. (2007) (6)
Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin (2004) (6)
Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor. (1999) (6)
Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. (1992) (6)
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide. (2002) (5)
Efficient lipofection with cisplatin-resistant human tumor cells. (1996) (5)
The synthesis and cytotoxic activity of some haloacetamidoalkyl β-D-xylopyranosides (1979) (5)
High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. (2018) (5)
Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors. (2000) (5)
Cell division cycle 25B phosphatase is essential for benzo(a)pyrene-7,8-Diol-9,10-epoxide induced neoplastic transformation. (2007) (5)
Rear-view mirrors and crystal balls: a brief reflection on drug discovery. (2008) (5)
Pulmonary fate of (/sup 3/H)bleomycin A2 in mice (1984) (4)
Introduction to Chemotherapy (2003) (4)
Solubility, ionization, and partitioning behavior of unsymmetrical disulfide compounds: alkyl 2-imidazolyl disulfides. (2002) (4)
Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin (2020) (4)
Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas. (1985) (4)
Molecular biology and anticancer drug discovery. (2010) (4)
In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. (1992) (4)
Disruption of insulin-like growth factor-1 signaling and down-regulation of cdc2 by SC-alphaalphadelta9, a novel small molecule antisignaling agent identified in a targeted array library. (1998) (3)
22 – Manipulation of Antineoplastic Drug Sensitivity and Resistance by DNA Transfection (1988) (3)
Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches (2018) (3)
PTP4A3 phosphatase promotes VEGF signaling and enables endothelial cell motility (2013) (3)
In Vivo Antitumor Activity and Induction of Insulin-Like Growth Factor-1-Resistant Apoptosis by SC-ααδ9 (2000) (3)
Novel protein kinase D inhibitors cause potent arrest in cancer cell growth and motility (2010) (3)
Metals and Anticancer Drug Resistance (1995) (3)
Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer (2021) (3)
The hubris and humility of cancer pharmacology in the post immuno‐oncology era (2019) (3)
Chemical synthesis and biological activity of a novel fluorescent etoposide derivative. (1997) (3)
NAD ( P ) H : Quinone Oxidoreductase-1-Dependent and-Independent Cytotoxicity of Potent Quinone Cdc 25 Phosphatase Inhibitors (2004) (3)
Structural basis for the sequence selectivity of DNA cleavage by bleomycins. (1993) (2)
Redox regulation of Cdc25B by novel cell active quinolinediones (2005) (2)
Changes and challenges--the world post-Gleevec (Glivec). (2002) (2)
Hep 3 B cells treated with an inhibitor of Cdc 25 dual-specificity phosphatases (2001) (2)
Transcriptome and Translatome Regulation of Pathogenesis in Alzheimer's Disease Model Mice (2022) (2)
Separation of bleomycins and their deamido metabolites by high-performance cation-exchange chromatography. (1990) (2)
22R-Hydroxycholesterol and 9-cis-retinoic acid induce ABCA1 transporter expression and cholesterol efflux in brain cells and decrease Aβ secretion* (2003) (2)
Faculty of 1000 evaluation for In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. (2018) (2)
Faculty of 1000 evaluation for Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. (2018) (2)
Immobilized adriamycin: toxic potential in vivo and in vitro. (1989) (2)
Metallothioneins and Cisplatin Resistance (1991) (2)
Effect of Pharmacological Inhibition of the Catalytic Activity of Phosphatases of Regenerating Liver in Early T Cell Receptor Signaling Dynamics and IL-2 Production (2020) (2)
Single intratracheal exposure to SARS‐CoV‐2 S1 spike protein induces acute lung injury in K18‐hACE2 transgenic mice (2021) (1)
Multimodal Control of Cdc 25 A by Nitrosative Stress (2008) (1)
Faculty Opinions recommendation of Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. (2012) (1)
Overexpression of metallothionein decreases sensitivity of pulmonary endothelial cells to oxidant injury. (1997) (1)
General Discussion 2 (1994) (1)
Combination of Subtherapeutic Doses of Tretazicar and Liposomal Amphotericin B Suppresses and Cures Leishmania major-Induced Cutaneous Lesions in Murine Models. (2021) (1)
Drug toxicity in the newborn (1985) (1)
Independent Mechanistic Inhibition of Cdc 25 Phosphatases by a Natural Product (2006) (1)
Organ directed toxicities of anticancer drugs : proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs, convened in Burlington, Vermont by the Vermont Regional Cancer Center, June 4-6, 1987 (1988) (1)
CHAPTER 15 – THE USE OF BLEOMYCIN IN MODEL SYSTEMS TO STUDY THE PATHOGENESIS OF INTERSTITIAL PULMONARY FIBROSIS (1993) (1)
Review for USMLE : United States medical licensing examination. (1992) (1)
Faculty Opinions recommendation of Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. (2006) (1)
O-9-125 Induction of apoptosis and growth regulation of malignant gliomas: UCN-01, a selective inhibitor of protein kinase C, blocks glioma proliferation in vitro (1997) (1)
Synthesis and Evaluation of Bifunctional PTP4A3 Phosphatase Inhibitors Activating the ER Stress Pathway. (2021) (1)
Molecular mechanisms of bleomycin resistance in human tumor cells (1986) (1)
Faculty Opinions recommendation of Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. (2017) (1)
Therapeutic Discovery Targeting Subcellular Localization through the Polo-Box Domain : Non-ATP Competitive Inhibitors Recapitulate a PLK 1 Phenotype (2012) (1)
Progression in Colon Cancer Cells microRNA-21 Negatively Regulates Cdc 25 A and Cell Cycle (2009) (1)
Expression in Human Bronchial and Lung Cancer Cells 1 (2003) (1)
Faculty Opinions recommendation of Genomics and evolution of protein phosphatases. (2017) (1)
Faculty Opinions recommendation of Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. (2018) (1)
Faculty of 1000 evaluation for Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras. (2018) (1)
NUMERICAL SIMULATIONS OF MICROSTRUCTURAL EVOLUTION OF IRON ALLOYS UNDER IRRADIATION (2013) (1)
The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons. (2020) (1)
Dual Specificity Protein Phosphatase 5 (2020) (1)
Extracellular cues accelerate neurogenesis of induced pluripotent stem cell derived neurons (2021) (1)
Phosphatidylserine signaling in apoptosis (1998) (1)
USMLE step 1 (1999) (1)
METALLOTHIONEIN (MT) REDUCES THE CYTOXICITY AND DNA DAMAGING EFFECTS OF NITRIC OXIDE (NO) (1994) (1)
Identification of Survival Genes in Human Glioblastoma Cells Using siRNA Screening (2009) (1)
The sphinx - a more appropriate Rorschach symbol Is it time for a change? (1985) (1)
Refining Radiation for the Next Century (2018) (0)
Accelerated Maturation of Non‐cycling Human Induced Pluripotent Stem Cell‐derived neurons for High Content Screening (2021) (0)
Polymer Immobilized Doxorubicin as A Regional Therapeutic Agent (1984) (0)
Figure 13, HTS scaffolds and associated data prior to validation from resynthesized solid materials (2011) (0)
Faculty Opinions recommendation of A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. (2012) (0)
Synthesis and Evaluation of Fluoromycin: A Novel Fluorescence-labeled Derivative of Talisomycin Siot,1 (2006) (0)
Faculty of 1000 evaluation for Synthetic essentiality: Targeting tumor suppressor deficiencies in cancer. (2018) (0)
An acute respiratory distress syndrome drug development collaboration stimulated by the Virginia Drug Discovery Consortium (2023) (0)
A Protein Tyrosine Phosphatase 4A3 (PTP4A3) inhibitor prevents and repairs pulmonary endothelial barrier dysfunction and ameliorates acute lung injury provoked by the SARS‐CoV‐2 Spike protein subunit 1 in k18‐hACE2 transgenic mice (2022) (0)
[Table, Profiling Assays]. (2011) (0)
The LXR ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer’s disease (2004) (0)
Transcriptional and translational regulation of pathogenesis in Alzheimer’s disease model mice (2021) (0)
Faculty Opinions recommendation of Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint. (2009) (0)
Figure 2, Known TbHK1 inhibitors and preliminary associated data (2011) (0)
Faculty Opinions recommendation of DNA damage response to the Mdm2 inhibitor nutlin-3. (2009) (0)
Abstract #3101: PRL-2 knockdown inhibits tumor cell migration and invasion (2009) (0)
47 Targeting Ptp4a3 in Colon Tumorigenesis and Cancer Progression (2012) (0)
Predoctoral Training in Breast Cancer Biology and Therapy. (1996) (0)
Small Molecule Inhibitors of Trypanosoma brucei Hexokinase 1 (2011) (0)
Abstract 5495: Identification of chemosensitivity nodes and small molecule inhibitors for breast cancer stem cell proliferation and survival (2010) (0)
Abstract 2540: Cytotoxicity, pharmacokinetics and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc (2010) (0)
Gene Therapy: Definition and Goals Gene Therapy (0)
Abstract 1220: Coordinated chemical-genetics approach identifies PTP4A3-mediated regulation of colon cancer cell migration and extracellular matrix interactions (2017) (0)
Table 1, Comparison of data obtained with variable quercetin sources (2011) (0)
Abstract 1459: PTP4A3 phosphatase is a novel drug target for epithelial ovarian cancer (2021) (0)
tor Regulation after Transfection into a Cell Line Deficient in the cAMP-Dependent (1989) (0)
Figure 7, Stability data depicted as a graph showing the loss of ML205 with time over a 48 hr period (2011) (0)
Rule Pathway The Substrate Recognition Domains of the Modification , and Degradation : Protein Synthesis , Post-Translational (2008) (0)
Advances in Brief Metallothionein Localization and Cisplatin Resistance in Human Hormone-independent Prostatic Tumor Cell Lines 1 (2006) (0)
Crystal structure of Human Serum Albumin complex with JMS-053 (2020) (0)
Faculty Opinions recommendation of High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. (2006) (0)
Abstract PR009: The functional genomic landscape of recurrent glioblastoma (2021) (0)
Table 3, SAR summary for substitution on the benzoic acid moiety (2011) (0)
Faculty of 1000 evaluation for Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. (2018) (0)
Disposition of radioiodinated benzylguanidines in perfused rabbit lung: pharmacokinetics and effect of an organo-gold complexed antineoplastic agent. (1990) (0)
Faculty of 1000 evaluation for Regulatory mechanisms and novel therapeutic targeting strategies for protein tyrosine phosphatases. (2018) (0)
Faculty Opinions recommendation of Silver enhances antibiotic activity against gram-negative bacteria. (2013) (0)
Faculty of 1000 evaluation for Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. (2018) (0)
Abstract 2365: A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion (2018) (0)
Faculty Opinions recommendation of Identifying the amylome, proteins capable of forming amyloid-like fibrils. (2010) (0)
and hDM2 and Characterization of the Confirmed Hits Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53 (2013) (0)
In the forefront of basic and translational cancer research - 7th AACR-JCA Joint International Conference. (2007) (0)
Synthesis, Molecular Modeling, 2‐D NMR, and Biological Evaluation of ILV Mimics as Potential Modulators of Protein Kinase C. (1993) (0)
Faculty Opinions recommendation of Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates. (2018) (0)
Abstract 3258: Targeted-deletion of Ptp4a3 suppresses murine colon tumorigenesis (2012) (0)
Table 5, SAR summary for modification of the amidoaryl component (2011) (0)
Hypoxia-mediated down regulation of the cell cycle phosphatase Cdc25A in colon cancer cells (2007) (0)
The Mechanism of Inhibition of the Undrugged Oncogenic Phosphatase PTP4A3 by a Novel Small Molecule JMS‐053 (2019) (0)
Faculty Opinions recommendation of Identification of stem cells in small intestine and colon by marker gene Lgr5. (2009) (0)
Figure 8, General synthetic route for probe and analogue synthesis (2011) (0)
Faculty Opinions recommendation of A comprehensive map of molecular drug targets. (2017) (0)
Pharmacology goes phlat: molecular interventions feels the impact. (2007) (0)
Nitric oxide regulates Cdc25A phosphatase expression (2006) (0)
Subject Index to Volume 15 (2001) (0)
Morphological differentiation and acetylcholine content in neuroblastoma cells (1974) (0)
Abstract #4774: Discovery of a potent and selective small molecule inhibitor of PKD functionality (2009) (0)
Award Number : DAMD 17-001-0412 TITLE : Novel Thioredoxin Inhibitors for Breast Cancer Therapy (0)
Subcellular localization mediated functioning of metallothionein: Protection against oxygen radicals and anticancer agents (1999) (0)
The Future of Pharmacology (2009) (0)
Abstract 202: Depletion of PTP4A3 phosphatase disrupts colorectal cancer cell adhesion and extracellular matrix interactions (2016) (0)
Faculty Opinions recommendation of Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. (2010) (0)
Table 2, SAR summary for compounds with carboxylic acid isosteric replacements (2011) (0)
Organ-directed toxicology of antitumor agents. Symposium summary. (1985) (0)
Molecular interventions (2001-2011): an experiment completed. (2011) (0)
The effects of haloacetamidoalkyl beta-d-xylopyranosides on melanoma cell division, detachment and glycosamino- glycans. Abstr. (1979) (0)
Faculty Opinions recommendation of A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. (2011) (0)
Enhancement of experimental lung metastases by melanoma cells treated with icrf-159. Abstr. (1978) (0)
Faculty Opinions recommendation of mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. (2013) (0)
P4-332 LXR ligand treatment in vitro and in vivo is followed by ABCA1 upregulation and decrease in AB secretion (2004) (0)
Desperately seeking genotype-selective anticancer agents. (2003) (0)
Faculty of 1000 evaluation for PARP inhibitors: Synthetic lethality in the clinic. (2018) (0)
Alterations in fucose metabolism of sarcoma 180 cells by 6-thioguanine (6gt). (1977) (0)
Dissecting the antimitotic activities and cellular actions of the natural product disorazole C1 (2008) (0)
Abstract 1460: The design and biological characterization of PTP4A-targeted chemodegraders (2021) (0)
Figure 10, Assembly of probe compound ML205, SID 99437306, CID 46931017 (2011) (0)
[Table, Planned Future Studies]. (2011) (0)
Genotyping Predicts Osteoporosis Risk after Lung Transplantation. (2020) (0)
Table 7, Comparison of quercetin and probe (2011) (0)
[Table, Structure Verification and Purity: 1H NMR, 13C NMR, LCMS and HRMS]. (2011) (0)
Protein Kinase C Processes and Their Relation to Apoptosis in Human Breast Carcinoma Cells. (1997) (0)
TRANSCRIPTION FACTOR DIFFERENCES IN CISPLATIN RESISTANT CELLS (1996) (0)
Pharmacological profiling of phosphoinositide-3-kinase inhibitors as mitigators of ionizing radiation-induced cell death (2013) (0)
Faculty Opinions recommendation of The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity. (2007) (0)
Faculty Opinions recommendation of Synthetic lethality and cancer. (2018) (0)
Cellular Sensitization to m-Diamminedichloroplatinum(II) by Novel Analogues of the Protein Kinase C Activator Lyngbyatoxin A1 (2006) (0)
Figure 14, [A. probe structure; B. dose...]. (2011) (0)
Abstract A83: Profiling potent, novel protein tyrosine phosphatase 4A3 small molecule inhibitors for ovarian cancer. (2016) (0)
Faculty Opinions recommendation of Differential mitotic degradation of the CDC25B phosphatase variants. (2007) (0)
Figure 1, Currently available marketed drugs for treatment of human African trypanosomiasis (2011) (0)
Faculty Opinions recommendation of Using a stem cell-based signature to guide therapeutic selection in cancer. (2011) (0)
The Antisignaling Agent SC- (cid:1)(cid:1)(cid:2) 9, 4-(Benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)-2-decanoylaminobutyricAcid,IsaStructurallyUniquePhospholipidAnaloguewithPhospholipaseCInhibitoryActivity (2002) (0)
Identification of Ionizing Irradiation Damage Mitigators by Evaluation of Clonogenic Survival of Human Umbilical Cord Blood Progenitor Cells (2012) (0)
Faculty Opinions recommendation of Common pitfalls in preclinical cancer target validation. (2018) (0)
Faculty Opinions recommendation of Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. (2008) (0)
General discussion 1 (1994) (0)
Anticancer Drugs Metallothionein Null Cells Have Increased Sensitivity to Updated Version (2006) (0)
Figure 9, Five analogues selected for submission to support probe ML205, SID 99437306, CID 46931017 and associated data (2011) (0)
Faculty Opinions recommendation of Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. (2010) (0)
Synthesis and Biological Studies of Simplified Analogues of Lyngbyatoxin A: Use of an Isoxazoline-Based Indole Synthesis. Quest for Protein Kinase C Modulators. (1989) (0)
Faculty of 1000 evaluation for Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. (2018) (0)
Faculty Opinions recommendation of PRL2 links magnesium flux and sex-dependent circadian metabolic rhythms. (2017) (0)
Synthesis and Biological Evaluation of Caulibugulones A—E. (2004) (0)
Functionome Alkylation Sensitivity Screens Reveal a Conserved Cross-species (2012) (0)
Faculty of 1000 evaluation for Synthetic lethality screens point the way to new cancer drug targets. (2018) (0)
of CD8 T Cell Responses in Antigen Presentation and the Generation Analysis of the Role of Bleomycin Hydrolase (2007) (0)
Abstract 2532:In vitrocytotoxicity, and pharmacokinetics, tissue distribution, and metabolism of the protein kinase D inhibitors, kb-NB142-70 and kb-NB184-43, in mice bearing human cancer xenografts (2010) (0)
Faculty Opinions recommendation of Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment. (2011) (0)
291. Aromatase activity in ovarian cancer (1982) (0)
Effect of PRL‐3 phosphatase knockout in cancer and angiogenesis (2011) (0)
Figure 15, Fused amide analogs and associated data (2011) (0)
An unusual case of self-defense (2009) (0)
Faculty Opinions recommendation of NanoLC-MS/MS analysis provides new insights into the phosphorylation pattern of Cdc25B in vivo: full overlap with sites of phosphorylation by Chk1 and Cdk1/cycB kinases in vitro. (2008) (0)
Cross-species Functionome Alkylation Sensitivity Screens Reveal a Conserved (2012) (0)
Review for USMLE (2013) (0)
Combinatorial Approach for Novel Phosphatase Inhibitors (2000) (0)
Small molecule PTP4A3 phosphatase inhibitors targeting acute myeloid leukemia (2020) (0)
Faculty Opinions recommendation of Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion. (2009) (0)
Identification of novel chemosensitivity nodes for vinblastine using siRNA synthetic lethal screens (2011) (0)
Modulation of calyculin a-induced apoptosis in lung cancer cells by serum and cell density (1996) (0)
Table 6, Survey of combined effects of optimized functionality (2011) (0)
Review for national board comprehensive part I examination (1991) (0)
DAMD 1794-J-4193 TITLE : Protein Kinase C Processes and Their Relation to Apoptosis in Human Breast Carcinoma Cells (0)
Pharmacology : PreTest self-assessment and review (1983) (0)
Druggable Genome siRNA-Screening Identifies Glybenclamide as a Radioprotector against Total Body Irradiation (2008) (0)
Disorazole C1: A potent antimitotic agent that induces premature senescence (2007) (0)
Faculty Opinions recommendation of Senolytics improve physical function and increase lifespan in old age. (2018) (0)
Figure 17, Michaelis-Menten and Lineweaver-Burk plots showing mixed inhibition of TbHK1 with respect to ATP using ML205, SID 99437306, CID 46931017 (2011) (0)
Ptp4a3 is expressed in AOM-DSS derived colon tumors and normal tissue. (2013) (0)
Novel Thioredoxin Inhibitors for Breast Cancer Therapy (2002) (0)
Table 4, SAR summary for substitution of the amide linker region (2011) (0)
[Table], User Chromatogram Peak List (2011) (0)
Substrate specificity studies of bleomycin blm hydrolase (1987) (0)
Figure 12, [A: plot of percent inhibition...]. (2011) (0)
Abstract 5210: PRL-1 promotes cell metastatic processes and regulates filamentous actin dynamics (2010) (0)
Faculty Opinions recommendation of Targeting tyrosine phosphatases: time to end the stigma. (2018) (0)
Figure 16, Select examples of cellular IMR90 and percent BSF inhibition data (2011) (0)
Pulmonary Metabolic Inactivation of Bleomycin and Protection from Drug-Induced Lung Injury (1988) (0)
Early phase pharmacokinetics and pulmonary disposition of parenteral bleomycin A2 (BLM A2) in BLM sensitive and resistant strains of mice (1986) (0)
Faculty Opinions recommendation of The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. (2016) (0)
Volume Contents (2004) (0)
In vivo antitumor activity and induction of insulin-like growth factor-1-resistant apoptosis by SC-alphaalphadelta9. (2000) (0)
Deactivation of STAT3 and ERK and Activation of p38 in Ovarian Cancer Cells Treated with a Small Molecule Inhibitor of PTP4A3 Phosphatase (2022) (0)
Novel Combinatorial Chemistry-Derived Inhibitors of Oncogenic Phosphatases. (2000) (0)
Figure 11, Triage of HTS hits and progression to meet probe criteria (2011) (0)
STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA (2019) (0)
Faculty Opinions recommendation of VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. (2011) (0)
Is a step backwards in S-phase-targeted chemotherapy a step forward? (2008) (0)
JPET #59477 1 NAD(P)H:quinone oxidoreductase-1 (NQO1)-dependent and –independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors (2003) (0)
Abstract 3210: Targeting PTP4A3 phosphatase in ovarian cancer with the potent noncompetitive inhibitor JMS-631-053 (2017) (0)
Live Long and Prosper (2005) (0)
Sleuthful pharmacology. (2003) (0)
AKMC modelling of FeCuNiMnSiP alloys under ion irradiation conditions (2019) (0)
Nitrosative Stress Triggers Inhibition of DNA Synthesis and Translational Suppression of Positive Cell Cycle Regulators (2008) (0)
The PTP4A3 Inhibitor, KVX-053, Ameliorates Alcohol-exacerbated SARS-CoV-2-induced ARDS (2023) (0)
Probing the role of the potent microtubule disrupting agent disorazole C1 in premature cellular senescence induction (2008) (0)
KVX-053, a PTP4A3 inhibitor, as antidote against CEES-induced Acute Lung Injury (2022) (0)
Identification of novel chemosensitivity nodes using siRNA synthetic lethal screens (2010) (0)
A potent and selective allosteric PTP4A3 phosphatase inhibitor enhances microvascular barrier function and inhibits human tumor cell growth. (2018) (0)
Disruption of Ovarian Cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase (2023) (0)
Exploiting small molecule and siRNA libraries to identify novel mechanisms for potential cancer therapeutic agents. (2008) (0)
Next Generation Potent Cell‐active Inhibitors of the Oncogenic PTP4A3 Phosphatase (2019) (0)
Abstract 5500: A PTP4A3 inhibitor reduces ovarian cancer dissemination and alters STAT3 and ERK activation (2022) (0)
Discovering potent PTP4A3 phosphatase small molecule inhibitors for colorectal cancer (2016) (0)
High content screening miniaturization and single cell imaging of mature human feeder layer-free iPSC-derived neurons. (2022) (0)
Disruption of the PI3K axis abrogates ionizing radiation‐induced cell death (2013) (0)

This paper list is powered by the following services:

Other Resources About John S. Lazo

en.wikipedia.org

What Schools Are Affiliated With John S. Lazo?

John S. Lazo is affiliated with the following schools:

John S. Lazo's Academic­Influence.com Rankings

John S. Lazo's Degrees

Why Is John S. Lazo Influential?

John S. Lazo's Published Works

Published Works

Other Resources About John S. Lazo

What Schools Are Affiliated With John S. Lazo?

John S. Lazo's AcademicInfluence.com Rankings